H
Hainan Poly Pharm Co Ltd
SZSE:300630
Hainan Poly Pharm Co Ltd
SZSE:300630
Price:
0.89
CNY
Market Closed
Market Cap:
¥68.4m
Relative Value
There is not enough data to reliably calculate the relative value of Hainan Poly Pharm Co Ltd.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
Not Available
Multiples Across Competitors
Competitors Multiples
Hainan Poly Pharm Co Ltd Competitors
Hainan Poly Pharm Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
H
|
Hainan Poly Pharm Co Ltd
SZSE:300630
|
68.4m CNY | 0 | -5.5 | 1 989.9 | 1 989.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
951.3B USD | 14.6 | 46.1 | 31.1 | 33.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
595.7B USD | 6.3 | 22.2 | 15.4 | 18.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
285.2B CHF | 4.7 | 30.6 | 12.9 | 15.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
243.7B CHF | 5.6 | 22.6 | 13.9 | 17.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232.2B GBP | 5.3 | 30.7 | 16.9 | 23.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.5B USD | 4.6 | 16.3 | 10.1 | 12.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.4 | 7.7 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 2.4 | 19.5 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.5B USD | 2.6 | 17.6 | 7.4 | 9.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
